Brain IschemiaCSINCT06270927
A Feasibility Study for Randomization of Code Stroke Imaging Strategies
An observational study of Brain Ischemia, run by University of Texas at Austin at 1 site in United States.
Trial summary
The purpose of this study is to test feasibility of a comparative effectiveness framework for acute stroke imaging using prospective electronic health data. This is a prospective, cohort feasibility study of patients presenting to the Emergency Department with suspected acute ischemic stroke. Read more about this study
- Who is it for?
- Ages 18 to 120 yearsHealthy volunteers can take part
- Conditions the study is for
- Brain Ischemia
- What is being tested?
- MRI and CT
- How many people
- 600 participants
- Where
- 1 siteUnited States
- Study dates
- 23 Oct 2023to 31 May 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 120 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients presenting as Code Stroke to Emergency Department at one of four network stroke centers
Who may be able to join
- Age ≥ 18 years
- Time last known well to presentation ≤ 24 hours
- Code-stroke (suspected treatable ischemic stroke) called prior to or upon arrival to Emergency Department
- Presenting to Emergency Department for first time during study period
Who cannot join
- Transfer patients
- Contraindication for brain perfusion scan
- Prior inclusion in study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: • Code Stroke Imaging (CSI): MRI Or CT As First Scan For Acute Stroke Evaluation And Management
The purpose of this study is to test feasibility of a comparative effectiveness framework for acute stroke imaging using prospective electronic health data. This is a prospective, cohort feasibility study of patients presenting to the Emergency Department with suspected acute ischemic stroke. The clinical stroke team will not be blinded to the imaging modality given the nature and purpose of the interventions/imaging. Knowledge of the imaging modality used and the knowledge gained from the resulting data will need to be considered for treatment decisions. Blinding will be maintained for data abstraction and analyses. Analysis will be on an "intent-to-scan" basis and all qualifying patients will be included in their assigned cohort.
Read the detailed description
The purpose of this study is to test feasibility of a comparative effectiveness framework for acute stroke imaging using prospective electronic health data. This is a prospective, cohort feasibility study of patients presenting to the Emergency Department with suspected acute ischemic stroke. The clinical stroke team will not be blinded to the imaging modality given the nature and purpose of the interventions/imaging. Knowledge of the imaging modality used and the knowledge gained from the resulting data will need to be considered for treatment decisions. Blinding will be maintained for data abstraction and analyses. Analysis will be on an "intent-to-scan" basis and all qualifying patients will be included in their assigned cohort.
All patients will receive standard-of-care therapy and management based on AHA/ASA clinical practice guidelines. For patients with emergent large vessel occlusions, this will include adjuvant endovascular therapy if criteria, as stipulated in the guideline, are met. Although this is referred to as a prospective study, no data collection will occur until after standard of care procedures.
Population: "Code-Stroke" (potentially-treatable) patients, defined as patients presenting with clinical syndrome suggestive of stroke within 24-hours of time last known well will be included.
Setting: four certified stroke centers (Ascension Seton Williamson, Ascension Seton Medical Center, Ascension Seton Hayes, and Dell Seton Medical Center)
Rationale: There is current equipoise in selection of first scan modality for code stroke. The time-dependent efficacy of treatment with thrombolytics increases diagnostic burden on the stroke team, particularly less experienced providers. In efforts to minimize door to needle time (DTN), stroke mimics may be inadvertently treated with thrombolytics, particularly when insensitive diagnostics are used. The investigators plan to examine feasibility of comparing CT-first versus MR-first strategies to guide the development of a future large multicenter comparison.
Methodology: The first-scan imaging modality will be assigned using two different schemes, a) clustered by hospital site and b) per-patient. Each scheme will be developed by a UT statistician or study team member, please see details in Randomization Schemes section below.
All practices will follow standard of care methods, no investigational procedures or interventions will occur as part of this study. A stroke alert is called prior to the arrival of the patient to the Emergency Department (ED). With this, patient information is communicated by the Emergency Medical Services team to the care team at the destination hospital to determine if the patient is potentially treatable (Code-Stroke).
Patient enrollment. Once a Code-Stroke is called, this will establish the patient eligible for the study and they will be enrolled. All stroke alerts are communicated via text message to the care team. The charge nurse leads a huddle prior to the arrival of each Code-Stroke patient. At the time the Code-Stroke is called, the first-scan imaging modality will be assigned and the patient will be enrolled.
Communication of assigned first-scan modality. The assigned first-scan imaging modality will be communicated via the ED charge nurse to all members of the care team including attending physicians, residents, and nursing staff. The mode of communication will be site-specific and include any of the following: verbal communication at initial pre-arrival stroke-alert huddle, sign posted at charge nurse desk that can be flipped to either "MRI" or "CT" typed in large letters, sign at scanners, sign at ED entrance. This will ensure the entire care team is aware and reminded of the first-scan modality assigned. This procedure was developed in close collaboration with Emergency Medicine attendings along with ED Medical and Nursing Directors at each participating hospital site.
Randomization Schemes: The prospective study includes two phases in which different randomization schemes will be evaluated for feasibility. Randomization schemes will be established a priori by the study Biostatistician. The Phases are as follows:
- Multi-Center Hospital-Level Cluster Randomization - (Phase A) During the cluster randomized study period, everyone at the hospital is getting the same standard of care (diagnostic), the patient is not being randomized. The imaging modality used as first-scan for code stroke will be the hospital strategy and not determined on a per-patient basis. A randomization period equal to one-week in which the imaging modality will be either CT or MRI for all patients at the site. This will be implemented for a study length of 12 weeks. Within this 12-week period, 4-week blocks will be used to ensure balance in the assignment to either CT or MRI. Randomization schemes will be independent across the four participating sites and start will be staggered by one week.
This cluster randomization is designed to test feasibility of a comparative effectiveness framework using prospective electronic health data. This study design challenges the traditional research ethics paradigm. Rather than testing experimental, unproven interventions, the research question asks how interventions that are widely used compare, and deploys these interventions in ways consistent with good clinical practice at the hospital level.
- Per-Patient Randomization - (Phase B) During the per-patient randomization, the first-scan imaging modality will be assigned to each eligible patient. A block size of 10 patients will be implemented to ensure balance in assignment to CT and MRI. The accrual of patients to meet this 10-patient block will be specific to each hospital site. Enrollment will be 5 weeks in duration. Randomization will be independent across sites. The assigned imaging modality will be communicated prior to each Code-Stroke and posted at the charge nurse station in the ED. With this, the entire stroke care team will know the assignment for the next Code-Stroke patient prior to their arrival.
- Conditions
- Brain Ischemia
- Being tested
- MRI, CT
- Keywords
- Stroke, Neuroimaging
- Medical subject headings
- Brain Ischemia, Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MRIDiagnostic test
Also called magnetic resonance imaging
neuroimaging using MRI scanner
CTDiagnostic test
Also called computed tomography
neuroimaging using CT scanner
| Study group | Role | What they receive |
|---|---|---|
| MRI | patients assigned to MRI Receives: Diagnostic Test: MRI; Diagnostic Test: CT | |
| CT | patients assigned to CT Receives: Diagnostic Test: MRI; Diagnostic Test: CT |
What is being measured
The primary outcome is the main question the study is designed to answer.
compliance
adherence to assigned first-scan imaging modality quantified as number of cross-overs (i.e., MRI scheduled but CT performed) relative to the sample size.
Measured: Two phases will be included. Phase A: 12 weeks of cluster randomization with the initiation of each site staggered by 1 week, for a total of 15 weeks Phase B: 5 weeks of per-patient randomization Total time for enrollment: 20 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Feb 2024
- Study start23 Oct 2023
- Primary completion30 Dec 2025
- Study completion31 May 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Brain IschemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 600 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Texas at Austin
- Sponsor type
- University, hospital or other
- Collaborators
- Lone Star Stroke Research Consortium, Ascension Texas
- Responsible party
- Principal investigator, Adrienne Dula, University of Texas at Austin
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06270927
- Sponsor's protocol ID
- 00003830
- Acronym
- CSI
- Status last verified
- Apr 2026
- First submitted
- 12 Jan 2024
- Last updated
- 1 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 1 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- • Code Stroke Imaging (CSI): MRI Or CT As First Scan For Acute Stroke Evaluation And Management
- ClinicalTrials.gov ID
- NCT06270927
- Acronym / sponsor ID
- CSI / 00003830
- Conditions
- Brain Ischemia
- Keywords
- Stroke, Neuroimaging
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 600 participants (estimated)
- Lead sponsor
- University of Texas at AustinUniversity, hospital or other
- Collaborators
- Lone Star Stroke Research Consortium, Ascension Texas
- Study start
- 23 Oct 2023 (actual)
- Primary completion
- 30 Dec 2025 (actual)
- Study completion
- 31 May 2026 (estimated)
- First posted
- 21 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to test feasibility of a comparative effectiveness framework for acute stroke imaging using prospective electronic health data. This is a prospective, cohort feasibility study of patients presenting to the Emergency Department with suspected acute ischemic stroke. The clinical stroke team will not be blinded to the imaging modality given the nature and purpose of the interventions/imaging. Knowledge of the imaging modality used and the knowledge gained from the resulting data will need to be considered for treatment decisions. Blinding will be maintained for data abstraction and analyses. Analysis will be on an "intent-to-scan" basis and all qualifying patients will be included in their assigned cohort.
Detailed description
The purpose of this study is to test feasibility of a comparative effectiveness framework for acute stroke imaging using prospective electronic health data. This is a prospective, cohort feasibility study of patients presenting to the Emergency Department with suspected acute ischemic stroke. The clinical stroke team will not be blinded to the imaging modality given the nature and purpose of the interventions/imaging. Knowledge of the imaging modality used and the knowledge gained from the resulting data will need to be considered for treatment decisions. Blinding will be maintained for data abstraction and analyses. Analysis will be on an "intent-to-scan" basis and all qualifying patients will be included in their assigned cohort.
All patients will receive standard-of-care therapy and management based on AHA/ASA clinical practice guidelines. For patients with emergent large vessel occlusions, this will include adjuvant endovascular therapy if criteria, as stipulated in the guideline, are met. Although this is referred to as a prospective study, no data collection will occur until after standard of care procedures.
Population: "Code-Stroke" (potentially-treatable) patients, defined as patients presenting with clinical syndrome suggestive of stroke within 24-hours of time last known well will be included.
Setting: four certified stroke centers (Ascension Seton Williamson, Ascension Seton Medical Center, Ascension Seton Hayes, and Dell Seton Medical Center)
Rationale: There is current equipoise in selection of first scan modality for code stroke. The time-dependent efficacy of treatment with thrombolytics increases diagnostic burden on the stroke team, particularly less experienced providers. In efforts to minimize door to needle time (DTN), stroke mimics may be inadvertently treated with thrombolytics, particularly when insensitive diagnostics are used. The investigators plan to examine feasibility of comparing CT-first versus MR-first strategies to guide the development of a future large multicenter comparison.
Methodology: The first-scan imaging modality will be assigned using two different schemes, a) clustered by hospital site and b) per-patient. Each scheme will be developed by a UT statistician or study team member, please see details in Randomization Schemes section below.
All practices will follow standard of care methods, no investigational procedures or interventions will occur as part of this study. A stroke alert is called prior to the arrival of the patient to the Emergency Department (ED). With this, patient information is communicated by the Emergency Medical Services team to the care team at the destination hospital to determine if the patient is potentially treatable (Code-Stroke).
Patient enrollment. Once a Code-Stroke is called, this will establish the patient eligible for the study and they will be enrolled. All stroke alerts are communicated via text message to the care team. The charge nurse leads a huddle prior to the arrival of each Code-Stroke patient. At the time the Code-Stroke is called, the first-scan imaging modality will be assigned and the patient will be enrolled.
Communication of assigned first-scan modality. The assigned first-scan imaging modality will be communicated via the ED charge nurse to all members of the care team including attending physicians, residents, and nursing staff. The mode of communication will be site-specific and include any of the following: verbal communication at initial pre-arrival stroke-alert huddle, sign posted at charge nurse desk that can be flipped to either "MRI" or "CT" typed in large letters, sign at scanners, sign at ED entrance. This will ensure the entire care team is aware and reminded of the first-scan modality assigned. This procedure was developed in close collaboration with Emergency Medicine attendings along with ED Medical and Nursing Directors at each participating hospital site.
Randomization Schemes: The prospective study includes two phases in which different randomization schemes will be evaluated for feasibility. Randomization schemes will be established a priori by the study Biostatistician. The Phases are as follows:
- Multi-Center Hospital-Level Cluster Randomization - (Phase A) During the cluster randomized study period, everyone at the hospital is getting the same standard of care (diagnostic), the patient is not being randomized. The imaging modality used as first-scan for code stroke will be the hospital strategy and not determined on a per-patient basis. A randomization period equal to one-week in which the imaging modality will be either CT or MRI for all patients at the site. This will be implemented for a study length of 12 weeks. Within this 12-week period, 4-week blocks will be used to ensure balance in the assignment to either CT or MRI. Randomization schemes will be independent across the four participating sites and start will be staggered by one week.
This cluster randomization is designed to test feasibility of a comparative effectiveness framework using prospective electronic health data. This study design challenges the traditional research ethics paradigm. Rather than testing experimental, unproven interventions, the research question asks how interventions that are widely used compare, and deploys these interventions in ways consistent with good clinical practice at the hospital level.
- Per-Patient Randomization - (Phase B) During the per-patient randomization, the first-scan imaging modality will be assigned to each eligible patient. A block size of 10 patients will be implemented to ensure balance in assignment to CT and MRI. The accrual of patients to meet this 10-patient block will be specific to each hospital site. Enrollment will be 5 weeks in duration. Randomization will be independent across sites. The assigned imaging modality will be communicated prior to each Code-Stroke and posted at the charge nurse station in the ED. With this, the entire stroke care team will know the assignment for the next Code-Stroke patient prior to their arrival.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| MRI | – | Diagnostic Test: MRI, Diagnostic Test: CTpatients assigned to MRI |
| CT | – | Diagnostic Test: MRI, Diagnostic Test: CTpatients assigned to CT |
Who may qualify
- Ages
- 18 to 120 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients presenting as Code Stroke to Emergency Department at one of four network stroke centers
Key inclusion criteria (4 listed)
- Age ≥ 18 years
- Time last known well to presentation ≤ 24 hours
- Code-stroke (suspected treatable ischemic stroke) called prior to or upon arrival to Emergency Department
- Presenting to Emergency Department for first time during study period
Key exclusion criteria (3 listed)
- Transfer patients
- Contraindication for brain perfusion scan
- Prior inclusion in study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MRIAlso: magnetic resonance imagingneuroimaging using MRI scanner | Diagnostic test | CT, MRI |
| CTAlso: computed tomographyneuroimaging using CT scanner | Diagnostic test | CT, MRI |
Primary outcome
compliance
Time frame: Two phases will be included. Phase A: 12 weeks of cluster randomization with the initiation of each site staggered by 1 week, for a total of 15 weeks Phase B: 5 weeks of per-patient randomization Total time for enrollment: 20 weeks
adherence to assigned first-scan imaging modality quantified as number of cross-overs (i.e., MRI scheduled but CT performed) relative to the sample size.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 May 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Brain Ischemia
Recruiting
Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe
Stroke, Acute
Not yet recruiting
EEG Feedback-Based Vagus Nerve Stimulation for Post-Stroke Dysphagia
Ischemic Stroke, Post-stroke Dysphagia
RecruitingObservational study
Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
Moyamoya Disease, Moyamoya Syndrome
Recruiting
Impact of Atrial Fibrosis Surface Area on the Occurrence of Atrial Fibrillation in Patients With Ischemic Stroke of Undetermined Origin: a Prospective Cardiac MRI Pilot Study.
Stroke, Implantation of an Implantable Cardiac Monitor
Recruiting
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Tablet-01)
Brainstem Stroke, ALS
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Brain Ischemia, run by University of Texas at Austin at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 1 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
compliance (time frame: Two phases will be included. Phase A: 12 weeks of cluster randomization with the initiation of each site staggered by 1 week, for a total of 15 weeks Phase B: 5 weeks of per-patient randomization Total time for enrollment: 20 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2026.